Arcturus Therapeutics (ARCT) PT Lowered to $20 at Wells Fargo

Go back to Arcturus Therapeutics (ARCT) PT Lowered to $20 at Wells Fargo

Arcturus Therapeutics (ARCT) PT Lowered to $17 at Leerink Partners

October 23, 2025 6:33 AM EDT

Leerink Partners analyst Lili Nsongo lowered the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $17.00 (from $54.00) while maintaining a Outperform rating.

The analyst comments "We update our ARCT model following yesterdays underwhelming ARCT-032 data readout in CF (initial note here), as well as disclosures including (1) the addition of a... More